Payment overview · 2025
General Payments
$442.78
6 reported records · 2 companies
Healthcare provider profile · identity verified
Daniel Carrel, DO
Allopathic & Osteopathic Physicians|Internal Medicine · GRAND RAPIDS, MI · NPI 1831127158
Verified facts
What the public records show
CMS Open Payments records show Daniel Carrel, DO received $442.78 in general payments during 2025 across 6 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 72.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Austedo Xr.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Austedo by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Austedo Xr by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $320.65 | 72.4% | 5 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $122.13 | 27.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $363.28 | 5 |
| Education | $79.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $241.15 | 4 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $122.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 57 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 649 | 137 |
| Eliquis | Apixaban | 417 | 52 |
| Amlodipine Besylate | Amlodipine Besylate | 370 | 73 |
| Levothyroxine Sodium | Levothyroxine Sodium | 356 | 67 |
| Gabapentin | Gabapentin | 302 | 68 |
| Divalproex Sodium | Divalproex Sodium | 276 | 40 |
| Sertraline Hcl | Sertraline Hcl | 274 | 49 |
| Furosemide | Furosemide | 269 | 66 |
| Lisinopril | Lisinopril | 241 | 48 |
| Potassium Chloride | Potassium Chloride | 235 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 215 | 48 |
| Metformin Hcl | Metformin Hcl | 213 | 46 |
| Jardiance | Empagliflozin | 212 | 16 |
| Trazodone Hcl | Trazodone Hcl | 210 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 198 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 193 | 44 |
| Quetiapine Fumarate | Quetiapine Fumarate | 188 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 178 | 44 |
| Risperidone | Risperidone | 173 | 24 |
| Myrbetriq | Mirabegron | 168 | 18 |
| Levetiracetam | Levetiracetam | 149 | 25 |
| Mirtazapine | Mirtazapine | 147 | 31 |
| Carvedilol | Carvedilol | 139 | 38 |
| Losartan Potassium | Losartan Potassium | 132 | 26 |
| Xarelto | Rivaroxaban | 131 | 19 |
| Torsemide | Torsemide | 127 | 29 |
| Olanzapine | Olanzapine | 125 | 27 |
| Memantine Hcl | Memantine Hcl | 123 | 13 |
| Aripiprazole | Aripiprazole | 121 | 12 |
| Trulicity | Dulaglutide | 108 | 21 |
| Donepezil Hcl | Donepezil Hcl | 101 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 100 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 98 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 97 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 95 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 92 | 22 |
| Omeprazole | Omeprazole | 90 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 89 | 15 |
| Buspirone Hcl | Buspirone Hcl | 86 | 25 |
| Clozapine | Clozapine | 85 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 84 | 18 |
| Allopurinol | Allopurinol | 82 | 16 |
| Montelukast Sodium | Montelukast Sodium | 82 | 18 |
| Baclofen | Baclofen | 80 | 21 |
| Enulose | Lactulose | 74 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 73 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 72 | 34 |
| Latanoprost | Latanoprost | 70 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 13 |
| Lorazepam | Lorazepam | 63 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 22 |
| Tramadol Hcl | Tramadol Hcl | 58 | 20 |
| Austedo Xr | Deutetrabenazine | 57 | suppressed |
| Meloxicam | Meloxicam | 57 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 56 | 30 |
| Spironolactone | Spironolactone | 56 | 12 |
| Prednisone | Prednisone | 55 | 26 |
| Entresto | Sacubitril/Valsartan | 53 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 53 | suppressed |
| Scopolamine | Scopolamine | 52 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 52 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 51 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 51 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 51 | 18 |
| Methocarbamol | Methocarbamol | 49 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 47 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 47 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 47 | 14 |
| Pregabalin | Pregabalin | 46 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 45 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 43 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 40 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 39 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | suppressed |
| Finasteride | Finasteride | 38 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 38 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 38 | suppressed |
| Clonazepam | Clonazepam | 37 | 13 |
| Farxiga | Dapagliflozin Propanediol | 37 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 37 | suppressed |
| Atenolol | Atenolol | 36 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 36 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 36 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 36 | suppressed |
| Lacosamide | Lacosamide | 36 | 11 |
| Lactulose | Lactulose | 36 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 36 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 35 | 16 |
| Famotidine | Famotidine | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | suppressed |
| Lovastatin | Lovastatin | 34 | suppressed |
| Novolog Flexpen | Insulin Aspart | 34 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Austedo | Deutetrabenazine | 32 | suppressed |
| Haloperidol | Haloperidol | 32 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Simvastatin | Simvastatin | 32 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 31 | suppressed |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 29 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 28 | 12 |
| Ozempic | Semaglutide | 28 | suppressed |
| Alprazolam | Alprazolam | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 24 | 14 |
| Cephalexin | Cephalexin | 23 | 22 |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 23 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 23 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 22 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 22 | suppressed |
| Movantik | Naloxegol Oxalate | 22 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 19 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Silodosin | Silodosin | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Brilinta | Ticagrelor | 17 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 17 | suppressed |
| Timolol Maleate | Timolol Maleate | 17 | suppressed |
| Gemtesa | Vibegron | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Lubiprostone | Lubiprostone | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 15 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 15 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Olanzapine Odt | Olanzapine | 15 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 15 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Trospium Chloride | Trospium Chloride | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Viokace | Lipase/Protease/Amylase | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | 12 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $442.78 · 6 records | Teva Pharmaceuticals USA, Inc. | AUSTEDO XR, INGREZZA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Austedo Xr play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Teva Pharmaceuticals USA, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error